Tuberculosis

Infectious Disease·MeSH: Tuberculosis

Prevalence

30.0 / 100K

37 drugs in development·11 companies·17 clinical trials

Drug Pipeline by Phase

Approved(1)

Drug	Company
t-spot.tb	OXFORD IMMUNOTEC GLOBAL PLC (OXFD)

Phase 3(16)

Drug	Company
background regimen	GH Research PLC (GHRS)
BPaL	CYTOKINETICS INC (CYTK)
BPaLM	CYTOKINETICS INC (CYTK)
BPaQ	CYTOKINETICS INC (CYTK)
BPaQM	CYTOKINETICS INC (CYTK)
conditioning regimen a	GH Research PLC (GHRS)
conditioning regimen b	GH Research PLC (GHRS)
conditioning regimen c	GH Research PLC (GHRS)
conditioning regimen d	GH Research PLC (GHRS)
conditioning regimen e	GH Research PLC (GHRS)
Ethambutol	UNITED THERAPEUTICS Corp (UTHR)
Isoniazid	UNITED THERAPEUTICS Corp (UTHR)
Moxifloxacin	UNITED THERAPEUTICS Corp (UTHR)
Pyrazinamide	UNITED THERAPEUTICS Corp (UTHR)
Rifampin	UNITED THERAPEUTICS Corp (UTHR)
Rifapentine	UNITED THERAPEUTICS Corp (UTHR)

Phase 2(12)

Drug	Company
bedaquiline	GH Research PLC (GHRS)
Bedaquiline	Crinetics Pharmaceuticals, Inc. (CRNX)
Clofazimine	Crinetics Pharmaceuticals, Inc. (CRNX)
Delamanid	Crinetics Pharmaceuticals, Inc. (CRNX)
Ethambutol	Crinetics Pharmaceuticals, Inc. (CRNX)
h56	HWH International Inc. (HWH)
H56	Valneva SE (VALN)
H56	Applied Therapeutics, Inc. (APLT)
Isoniazid	Crinetics Pharmaceuticals, Inc. (CRNX)
mk-7762	GH Research PLC (GHRS)
Pyrazinamide	Crinetics Pharmaceuticals, Inc. (CRNX)
Rifampin	Crinetics Pharmaceuticals, Inc. (CRNX)

Phase 1(2)

Drug	Company
BNT164a1	BioNTech SE (BNTX)
BNT164b1	BioNTech SE (BNTX)

Preclinical(1)

Drug	Company
map vaccine	GENETHERA INC (GTHR)

Phase 4(5)

BioSniper tracks 37 drugs in development for Tuberculosis across 11 companies.

There are 17 clinical trials targeting Tuberculosis tracked by BioSniper.

The estimated prevalence of Tuberculosis is approximately 30.0 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.